कंपनी का अवलोकन
Longeveron Inc. operates as a clinical-stage biotechnology entity dedicated to developing cellular therapies designed to treat aging-related and life-threatening conditions within the United States market. The company functions within the broader Healthcare sector, specifically focusing on the Biotechnology industry, which implies a high-risk, high-reward environment characterized by significant research and development expenditures before products reach commercialization. Currently, the organization employs 38 individuals and maintains a market capitalization of $32.50M, while generating total revenue of $1.20M over the trailing twelve-month period. These financial dimensions indicate that Longeveron is a micro-cap enterprise with limited operational scale, suggesting that its current revenue base is insufficient to cover its substantial burn rate, thereby reflecting a position typical of early-stage development firms that rely heavily on external capital to fund their investigative pipeline.
वित्तीय स्वास्थ्य
Over the trailing twelve months, the company reported a revenue of $1.20M, yet this figure masks a net income loss of $22,704,000, revealing a cost structure where expenses significantly outweigh income generation. The EBITDA for the period stood at $-22,061,000, further highlighting the intense cash consumption inherent in the clinical development phase. Free cash flow was reported at $-11,171,375, indicating a negative cash position that limits financial flexibility and necessitates continuous fundraising to sustain operations. The gross margin stands at 67.0%, which suggests efficient cost of goods sold relative to revenue, while the operating margin of -1479.2% and profit margin of 0.0% underscore the severe operational inefficiencies driven by heavy administrative and R&D costs. On the liability side, the company holds $4.66M in cash against $824,000 in debt, resulting in a debt-to-equity ratio of 14.52, which signifies a highly leveraged balance sheet relative to equity, though the absolute debt load is manageable given the cash reserves. The current ratio is 1.33, indicating that the company possesses sufficient current assets to cover its short-term liabilities, albeit with a narrow margin of safety typical for biotech firms. Return on Equity is -164.7% and Return on Assets is -81.3%, metrics that reveal management is currently destroying shareholder value and utilizing assets to generate losses rather than returns.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is not applicable due to negative earnings, whereas the forward P/E is listed as -0.73, a metric that implies the market is pricing in continued losses or a lack of near-term profitability. The price-to-book ratio is 4.49, indicating that the market values the company at a significant premium over its net asset book value, likely reflecting the potential value of its intellectual property and clinical pipeline rather than tangible assets. Alternative valuation metrics such as the price-to-sales ratio of 27.11 and an EV/EBITDA of -1.00 suggest that traditional earnings-based valuation models are invalid, forcing reliance on sales multiples that are exceptionally high for a company with negative earnings. The stock has traded between a 52-week high of $1.83 and a 52-week low of $0.47, and without a specific current price provided in the facts, the valuation context relies on these historical bounds to gauge volatility. The beta is recorded as -0.19, a unique and anomalous statistic that suggests the stock price moves inversely to the broader market or exhibits negligible correlation, presenting an unusual risk profile distinct from standard biotechnology equities.
Growth & Income
Revenue growth year-over-year has declined by 39.5%, while earnings growth is not applicable due to the company's consistent losses, indicating that the business is contracting or failing to scale its revenue base to meet financial targets. As the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it follows a growth-oriented strategy where all available capital must be reinvested into research and development rather than distributed to shareholders. The absence of a dividend yield confirms that the firm prioritizes preserving cash for operational survival and clinical trial advancements over providing income to investors. Consequently, the overall growth and income profile is characterized by negative revenue momentum and a complete reliance on equity financing or cash reserves to fund future development stages without providing any current income stream to capital providers.